文献速递血管炎

美国系统性血管炎医保受益人的医疗利用与支出

Healthcare utilization and expenditures for United States Medicare beneficiaries with systemic vasculitis.
PubMed 文献 · Semin Arthritis Rheum · 2017-08-10

该回顾性研究基于2010年Medicare索赔数据,比较系统性血管炎(SV)与非SV受益人的医疗利用和支出。匹配年龄性别后,SV患者每年医疗支出多11004美元、处方药多773美元,几乎所有服务利用均更高。

要点

  • SV患者年度医疗支出约为非SV患者两倍
  • 除临终关怀外,SV患者所有服务利用均更高
  • 透析、再入院、住院和检查事件为2-3倍

核心结论

  • 匹配后SV患者年度医疗支出约翻倍,源于几乎所有类别服务利用增加。

研究设计与样本

  • 全国回顾性研究,使用2010年Medicare A/B部分索赔数据,SV组176498例,非SV随机对照组46561例。

主要发现

  • 匹配后Medicare为SV患者每人多支出11004美元医疗服务费和773美元处方药费。
  • SV患者自身多支出1547美元医疗服务费和211美元处方药费。
  • 除临终关怀外,SV患者所有服务利用更高,透析、再入院、住院和检查为2-3倍。

临床怎么用

  • 提示SV患者医疗负担重,临床管理需关注高利用服务如透析和再入院。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Medicare federal insurance program is the most common United States insurer of patients with systemic vasculitis (SV). We compared healthcare utilization and expenditures for Medicare beneficiaries with versus without SV. METHODS: This national, retrospective study used 2010 claims and enrollment data for a 100% cohort of Medicare Part A and B beneficiaries with ≥1 claim including a diagnosis for a form of SV (n = 176,498), and a randomly selected group of non-SV beneficiaries (n = 46,561). Outcomes included annual counts of events in 16 categories of medical services (e.g., inpatient stays, physician visits, tests, and imaging events), and total annual Medicare and patient medical expenditures. We used linear regression with bootstrapped standard errors to compare utilization and expenditures by SV status, before and after matching on age and sex. Prescription drug fills and expenditures for SV (n = 95,157) and non-SV (n = 24,992) beneficiaries with Part D drug benefits were also compared. RESULTS: After matching, Medicare spent $11,004 more per patient in 2010 for medical services, and $773 more on prescription drugs, for SV versus non-SV beneficiaries. SV beneficiaries spent $1547 more for medical services and $211 more for prescription drugs. Except for hospice, SV beneficiaries had greater utilization of all services, including two-to-three times more dialysis events, hospital readmissions, inpatient stays, skilled nursing facility stays, and medical tests. CONCLUSIONS: The average Medicare beneficiary with SV incurs about double the annual healthcare expenditures compared to their non-SV counterparts, attributable to increased utilization of almost all categories of care.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Thorpe CT, Thorpe JM, Jiang T, et al. Healthcare utilization and expenditures for United States Medicare beneficiaries with systemic vasculitis. Semin Arthritis Rheum. 2017. PMID: 28918956. doi:10.1016/j.semarthrit.2017.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。